$10.0M
$515K
7.8x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
The company is a well-established provider of durable medical equipment and home respiratory therapy services, serving both institutional and home-based patients. Founded in the early 1990s, the business has developed a strong operating platform with recurring revenue supported by long-term patient relationships and government-related contracts. The company is anticipating new VA contract awards and continued growth within its existing contracts.
Why we like it
- Earnings quality is backed by recurring, need-based demand. Home oxygen and respiratory therapy are not discretionary, and patients on long-term equipment generate predictable monthly reimbursement rather than one-time sales. The government and institutional contract base adds a layer of revenue that does not evaporate in a downturn.
- The moat is regulatory and relationship-driven. DME accreditation, Medicare/Medicaid/VA supplier enrollment, and payer contracts take years to build and create real switching friction for referral sources like hospitals and physicians. A 30-plus year operating history means the business has cleared the compliance and credentialing hurdles that keep new entrants out.
- Market tailwinds are demographic and durable. An aging Pennsylvania and national population drives structural growth in respiratory and mobility equipment demand, and home-based care continues to shift volume away from facilities. The anticipated new VA contract awards represent a concrete near-term growth catalyst on top of that secular trend.
- There is clear operator upside in the margin. At roughly 5 percent owner earnings on $10M in revenue, this business is under-optimized on billing, collections, and equipment utilization. An operator who tightens denial management and route efficiency can expand cash flow without adding a dollar of new revenue.
How to improve it
- Audit and rebuild the revenue cycle in the first 90 days. DME businesses bleed margin through denied claims, slow collections, and documentation gaps that trigger clawbacks. Bringing in a specialized billing lead or DME billing platform to reduce denial rates could move the 5 percent margin materially.
- Lock down and expand the VA contract pipeline. The listing flags anticipated new VA awards, so a buyer should immediately quantify the size and timing of those opportunities and put dedicated resources behind winning and onboarding them. VA revenue is high-quality and defensible if you can service it reliably.
- Improve equipment utilization and asset turns. Idle oxygen concentrators and CPAP units sitting in a warehouse are dead capital, so implement tracking to maximize rental fleet deployment and recover unreturned equipment. Higher turns directly lift return on the working capital tied up in devices.
- Diversify the payer mix to reduce reimbursement concentration. Heavy dependence on government payers exposes the business to rate cuts and competitive bidding cycles. Growing private-pay, private insurance, and cash-pay lines (like premium CPAP supplies and resupply programs) improves margin and reduces single-payer risk.
- Build a systematic resupply program. Patients on CPAP and respiratory equipment need recurring consumables like masks, tubing, and filters, and an automated resupply outreach engine turns a one-time sale into a recurring annuity. This is one of the highest-ROI, lowest-cost margin levers in DME.
- Deepen referral relationships with hospitals, pulmonologists, and discharge planners. Referral sources are the lifeblood of DME volume, so formalize a liaison function to protect and grow these channels. Consistent, fast fulfillment for discharge planners wins repeat volume and blocks competitors.
Diligence notes
- Scrutinize the payer mix and reimbursement exposure. Break down revenue by Medicare, Medicaid, VA, private insurance, and cash-pay, and model the impact of competitive bidding and rate changes. A business this dependent on government reimbursement lives and dies by policy, so understand the exposure fully.
- Verify the anticipated VA contract awards are real, not hopeful. The growth thesis leans on new VA contracts, so demand documentation: solicitations, bid submissions, scoring, or award notices. If these are speculative, the growth story is discounted and the 7.77x multiple looks rich.
- Confirm the multiple and what is actually being purchased. A $4M price on $515K cash flow is 7.77x, which is aggressive for a 5 percent-margin DME business, so clarify whether accreditation, contracts, rental fleet, and receivables all transfer cleanly. Understand how much value sits in the equipment fleet versus intangible contract goodwill.
- Run a compliance and audit-risk review. DME is one of the most heavily audited healthcare segments, with RAC and TPE audits that can trigger significant recoupments. Review historical audit findings, denial rates, and any outstanding overpayment liabilities before closing.
- Assess working capital and receivables quality. Government payers are slow, and thin-margin DME businesses can be strangled by DSO and aged receivables. Age the receivables, quantify bad debt, and confirm the buyer has enough working capital to fund the reimbursement lag.
- Understand why the owner is selling and the transition plan. The listing does not disclose a reason or a support commitment, so probe owner involvement in referral relationships and payer contracts. Key-person and referral-source risk needs to be quantified and mitigated with a defined handover.
Source
Want the full analysis on every deal? Unlock the complete platform with Accredited Pro to screen live listings and read our operator-level writeups.